Hansen Medical Names Rita Jacob Vice President for Training and Clinical Affairs
15 12월 2010 - 6:01AM
Marketwired
Hansen Medical, Inc. (NASDAQ: HNSN), a global leader in flexible
robotics and the developer of robotic technology for accurate 3D
control of catheter movement, today named industry veteran Rita V.
Jacob Vice President for Training and Clinical Affairs, effective
immediately. Jacob will report directly to President and CEO Bruce
Barclay.
Jacob, 50, has more than 20 years of experience in training,
technical support and clinical research in collaboration with both
vascular surgeons and interventionalists. Most recently she was
Director, Clinical Affairs, Vascular Therapies for San Jose,
California based Covidien, which acquired her previous employer
Bacchus Vascular, where she was Vice President, Clinical Affairs.
Before Bacchus, Jacob helped design and manage training and
clinical research of AAA (abdominal aortic aneurysm) stent grafts
for both Medtronic and Boston Scientific. Earlier in her career she
held multiple clinical sales and related positions with
Guidant.
"Rita has a breadth of expertise working closely with physicians
as the head of a global training effort, which is a capability we
will draw on at Hansen," Barclay said. "Training of both our field
based employees and the physicians and hospital staff using our
products in electrophysiology and vascular is critical to our
future success. Our planned entrance into the vascular market in
the coming year is a key milestone, and effective training will be
a cornerstone to a successful commercial launch. She has direct
experience in the global vascular market, which is important as we
move forward with the expected commercialization of our flexible
catheter vascular robotic system in both the US and Europe. After
commercial launch, designing and managing clinical research to
generate relevant data for clinicians and payors alike will also be
critical, and Rita has a long track record of success in this area
as well."
"I'm impressed with both the technology and management team
assembled to develop and commercialize this groundbreaking
technology," Jacob said. "I believe the benefit of the vascular
robotic system to the interventional physician and their patients
could be significant. It is an honor to have been sought out for
this challenging opportunity and I look forward to applying my
experience in vascular and minimally invasive therapies to deliver
positive results for Hansen Medical's stakeholders."
Jacob has a Bachelor of Science degree in nursing from the
University of Maryland and is a registered nurse.
About Hansen Medical, Inc. Hansen Medical,
Inc., based in Mountain View, California, develops products and
technology using robotics for the accurate positioning,
manipulation and control of catheters and catheter-based
technologies. The company's Sensei® system and its Sensei X Robotic
Catheter System were cleared by the U.S. Food and Drug
Administration for manipulation and control of certain mapping
catheters in electrophysiology (EP) procedures. This robotic
catheter system is compatible with fluoroscopy, ultrasound, 3D
surface map and patient electrocardiogram data. In the United
States, the Sensei System is not approved for use in guiding
ablation procedures; this use remains experimental. The U.S.
product labeling therefore provides that the safety and
effectiveness of the Sensei and Sensei X systems for use with
cardiac ablation catheters in the treatment of cardiac arrhythmias,
including atrial fibrillation (AF), have not been established
during EP procedures, such as guiding catheters in the treatment of
AF. In the European Union, the Sensei and the Sensei X systems are
cleared for use during EP procedures, such as guiding catheters in
the treatment of AF. The vascular robotic system requires
regulatory filings and approval and is not commercially available.
Additional information can be found at www.hansenmedical.com.
Forward-Looking Statements This press
release contains forward-looking statements that involve risks,
uncertainties, assumptions and other factors which, if they do not
materialize or prove correct, could cause Hansen's results to
differ materially from those expressed or implied by such
forward-looking statements. All statements, other than statements
of historical fact, are statements that could be deemed
forward-looking statements, including statements containing the
words "expected", "planned" and similar words. Hansen Medical
intends such forward-looking statements to be covered by the safe
harbor provisions for forward-looking statements contained in
Section 21E of the Exchange Act and the Private Securities
Litigation Reform Act of 1995. Examples of such statements include
statements about the expected timing of commercialization of our
investigational vascular robotic system, expectations regarding
data generated from any clinical research and the importance of
training on the commercial launch. Important factors that could
cause actual results to differ materially from those indicated by
forward-looking statements include, among others, potential safety
and regulatory issues that could delay, suspend or terminate
clinical studies, regulatory approvals or sales, challenges in
designing, engineering and manufacturing systems to function as
intended, uncertain timelines, costs and results of clinical trials
and development of new products, our ability to plan and manage
cost-reduction or operational efficiency initiatives, the scope and
validity of intellectual property rights applicable to products
being developed, and our ability to remediate material weaknesses
in internal controls over financial reporting. These and other
risks are described in greater detail under the heading "Risk
Factors" contained in our periodic SEC filings, including our
Quarterly Report on Form 10-Q filed with the SEC on November 9,
2010. Given these uncertainties, you should not place undue
reliance on the forward-looking statements in this press release.
We undertake no obligation to revise or update information herein
to reflect events or circumstances in the future, even if new
information becomes available.
Hansen Medical, Heart Design, Hansen Medical & Heart Design,
and Sensei are registered trademarks of Hansen Medical, Inc. in the
United States and other countries.
Investor Contacts: Peter Osborne Interim CFO Hansen
Medical 650.404.5800 Matt Clawson Allen & Caron Inc
949.474.4300 Email Contact
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Hansen Medical, Inc. (MM) (NASDAQ:HNSN)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024